Viralgen inaugurated its new MSAT (Manufacturing, Science and Technology) laboratory today at the Science and Technology Park of the Basque Country in Donostia. Opening this laboratory marks a milestone in the development of state-of-the-art research and production of advanced therapies. The laboratory combines clinical development activities with commercial production, accelerating the development and delivery of treatments for rare genetic diseases, thereby improving the lives of millions worldwide.

The inauguration ceremony was led by Jimmy Vanhove, CEO of Viralgen and TAAV, along with the Mayor of Donostia, Eneko Goia, Arantxa Tapia, the Basque Government’s Minister of Economic Development and Competitiveness, and Eider Mendoza, General Deputy of Gipuzkoa. Their presence underscores the joint commitment to advancing research, technological development, and the economic growth of the Basque Country. “This laboratory strengthens our mission to bring hope to patients through science and innovation, reaffirming our commitment to improving people’s health and well-being,” emphasized Jimmy.

The MSAT laboratory represents an investment of over 10 million euros, alongside ACE (Analytical Center of Excellence), another specialized analytical laboratory. This investment boosts the local economy and demonstrates a commitment to scientific advancement and public health improvement. MSAT plays a crucial role by combining initial clinical development activities with the production of Adeno-associated Virus (AAV) for advanced therapies. It features state-of-the-art facilities, a highly skilled team, and an innovative approach to integrating digital technology into all aspects of its operation.

With the implementation of electronic lab notebooks and advanced data management systems, MSAT ensures the efficient capture, analysis, and visualization of critical information in real-time. This digitalization not only enhances data integrity and traceability but also facilitates interdisciplinary collaboration and informed decision-making.

With a highly skilled team of researchers, the MSAT team at Viralgen is at the forefront of digitalization in gene therapy production, paving the way for more effective and accessible treatments for rare genetic diseases.